Acrux: The Bear Case

Just a month after we upgraded Acrux, the Financial Review has published the case for selling. That’s despite the most recent research finding testosterone replacement therapy (TRT) is safer than earlier studies suggested.

Read More

Acrux A Standout Life Science Play

Life science stocks are not the most preferred of plays in an uncertain economic environment but as with all sectors of the market it is necessary to sift through the sector to find those companies that have the potential to deliver solid investment returns even in the currently unfavourable market conditions.

Read More

Analyst Views